Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes
about
Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis.Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry.Molecular targets for selective killing of TRAIL-resistant leukemic cells.Leishmania donovani infection induces anemia in hamsters by differentially altering erythropoiesis in bone marrow and spleenMyelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.Usefulness of Adalimumab for Treating a Case of Intestinal Behçet's Disease With Trisomy 8 Myelodysplastic Syndrome.The biology of myelodysplastic syndromes: unity despite heterogeneity.Biology of BM failure syndromes: role of microenvironment and niches.CD34+ gene expression profiling of individual children with very severe aplastic anemia indicates a pathogenic role of integrin receptors and the proapoptotic death ligand TRAIL.The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 statusTargeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.TRAIL, caspases and maturation of normal and leukemic myeloid precursors.Antiproliferative and Apoptotic Effect of Curcumin and TRAIL (TNF Related Apoptosis inducing Ligand) in Chronic Myeloid Leukaemic CellsHeat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion KinaseMolecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.Following TRAIL's path in the immune system.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.TNF-α signaling in Fanconi anemia.Myelodysplastic syndromes: toward a risk-adapted treatment approach.Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells.The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40.Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation.Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells.SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.Pleomorphic adenoma gene-like 2 regulates expression of the p53 family member, p73, and induces cell cycle block and apoptosis in human promonocytic U937 cells.Conjunctival sac fluid contains elevated levels of soluble TRAIL: implications for the anti-tumoral surveillance of the anterior surface of the eye.The role of apoptosis and current therapeutic challenges in myelodysplastic syndromes.A 36-year-old woman with recurrent high-grade fevers, hypotension, and hypertriglyceridemia.TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications.Defective ribosome biogenesis in myelodysplastic syndromes.Levels of TNF-related apoptosis-inducing ligand (TRAIL) show a long-term stability in the breast milk of mothers of preterm infants.Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1.Human colostrum and breast milk contain high levels of TNF-related apoptosis-inducing ligand (TRAIL).Relationships between tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and hematopoietic activity in healthy adults.The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement.Over-expression of cancerous inhibitor of PP2A (CIP2A) in bone marrow cells from patients with a group of high-risk myelodysplastic syndromes.MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.
P2860
Q33696464-1A30A404-1FDB-496D-9FD5-45FA0B0633D1Q33747504-6311FC59-952E-4569-96BF-845126CDC21CQ33891400-D6E7D6DC-5076-4481-B6F9-DE1DB5452391Q34637852-85A57349-C7F3-40CF-92BB-95BD39D6DCF2Q35001132-23F5B76E-15E9-4E71-99B0-2BE97F62937EQ35136851-A5A7DBA2-C430-4693-BCFB-999FFAE53FA7Q35554192-A6A2AE63-4ECF-4E21-86E7-4E466DCF3666Q35567925-1D74FF76-2229-4F0D-96AF-6E75060F9959Q35568527-29927CBD-4153-4A42-8564-1DFFD8698E9DQ36216179-22D1DB08-7A38-475D-9822-418AFE583773Q36366626-539BB73A-2810-4327-9745-24BD6B921B79Q36547805-3D5A6216-0A52-487C-8732-0CB0E959AD86Q36590964-85E32B65-110F-4633-A756-773E1893072EQ36899138-670B59B6-634F-4368-AD82-C2629878D890Q37031282-1CB75EDD-72E6-4E45-8A40-E6EBC2F489EDQ37186801-744F5ACF-B684-478E-A988-D2D3B30C104EQ37498946-EDD94A4B-C729-4B6E-80A8-30AFB43524D4Q37864686-A007C4B6-E74C-4AC9-802C-96F8AC81CD97Q38061848-19FC2E28-A9BE-4C2C-B5EF-8E1CE32A2FE5Q38124483-D2C767AC-17DE-4247-BCBE-F40955E7713DQ38149315-DC31B934-B46D-4277-A5E2-9B30E0C3F25CQ39029498-2936D5C1-EFFD-4507-A81A-201F24083ED4Q39161098-7DD71DC7-4E83-4BD8-BFAA-1A89544BCEFFQ39256130-5400DC05-2CEF-4FC9-B9AA-89C72B541024Q39292824-AC7032F8-6B34-49CE-BE32-B4E6B91CC540Q39413526-A9E68807-B4D4-498E-8785-485A179C89D9Q39444603-4AEE75A8-AE38-4A38-831E-341E1BBB7279Q39941799-9C222A02-6772-41FB-91FB-441DD6187987Q40169436-44CB6689-1B77-492F-999B-24215D2B26B1Q40364988-E16D61CB-D5BF-49D3-AE53-8CE410E5288FQ41123139-4986350A-0703-4F71-9E34-B6779336E7E1Q42574001-8FF92263-D392-4184-B2B5-D9598CDCDC5BQ43414740-A255EEE1-C1CF-41A1-B355-980BD133E989Q44698226-F8C8CA2A-3E5B-409B-BBF8-F89432CED9BDQ45018784-5214E7BA-B5F8-4897-9986-84D4B41CCB4DQ45723535-2B144CEF-95A8-48DB-B651-E1C70A6673C0Q46593030-9FF71F66-0690-4808-BD13-522CE86B4BCDQ47832405-CE8D9FB8-0F77-4D24-92ED-286605358968Q53085100-15578236-E11A-405E-B8EC-65764EEC32A9Q54531407-84A7F3ED-0B44-46CA-8D1C-A341E8F93806
P2860
Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Evidence for a role of TNF-rel ...... a of myelodysplastic syndromes
@ast
Evidence for a role of TNF-rel ...... a of myelodysplastic syndromes
@en
type
label
Evidence for a role of TNF-rel ...... a of myelodysplastic syndromes
@ast
Evidence for a role of TNF-rel ...... a of myelodysplastic syndromes
@en
prefLabel
Evidence for a role of TNF-rel ...... a of myelodysplastic syndromes
@ast
Evidence for a role of TNF-rel ...... a of myelodysplastic syndromes
@en
P2093
P2860
P50
P1476
Evidence for a role of TNF-rel ...... a of myelodysplastic syndromes
@en
P2093
Elisabetta Melloni
Federica Corallini
Francesco Lanza
Giorgio Zauli
P2860
P304
P356
10.1016/S0002-9440(10)62277-8
P407
P577
2005-02-01T00:00:00Z